COVID-19 ON BEHÇET’S DISEASE PATIENT : SHED LIGHT ON SHADOWS (CASE REPORT)

Authors

  • Hanane Ezzouine Professor, Department of Anesthesiology and Intensive Care, Ibn Rochd University Hospital of Casablanca, Hassan II University, Morocco
  • Mehdi simou Department of Anesthesiology and Intensive Care, Ibn Rochd University Hospital of Casablanca, Hassan II University, Morocco
  • Aymane El louadghiri Department of Anesthesiology and Intensive Care, Ibn Rochd University Hospital of Casablanca, Hassan II University, Morocco
  • Mounir Louardi Department of Anesthesiology and Intensive Care, Ibn Rochd University Hospital of Casablanca, Hassan II University, Morocco
  • Imane Khaoury Department of Anesthesiology and Intensive Care, Ibn Rochd University Hospital of Casablanca, Hassan II University, Morocco
  • Akram Mansour Department of Anesthesiology and Intensive Care, Ibn Rochd University Hospital of Casablanca, Hassan II University, Morocco
  • Med Amine Abidi Department of Anesthesiology and Intensive Care, Ibn Rochd University Hospital of Casablanca, Hassan II University, Morocco
  • Boubaker Charra Department of Anesthesiology and Intensive Care, Ibn Rochd University Hospital of Casablanca, Hassan II University, Morocco

DOI:

https://doi.org/10.29121/granthaalayah.v8.i11.2020.1539

Keywords:

Covid-19, Patient, Shed Light

Abstract

A new family type of coronavirus (SARS-CoV-2) was first seen in Wuhan, China name coronavirus disease 2019 (COVID-19). COVID-19 primarily attacks the respiratory system, but several studies have shown that infection with SARS-COV-2 can cause thrombosis and have therefore considered COVID-19 to be a prothrombotic disease.

Behçet's disease (MB) is a systemic vasculitis. Its ethiopathogeny is still poorly understood. Blood vessels of any caliber can be affected. Arterial involvement, such as thrombosis and / or aneurysm, is possible.

This article reports the case of SARS-COV-2 infection in a patient with behcet's disease.

Downloads

Download data is not yet available.

References

Klok FA, Kruip MJHA, van der Meer NJM et al (2020) Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. DOI: https://doi.org/10.1016/j.thromres.2020.04.041

https ://doi.org/10.1016/j.throm res.2020.04.041 DOI: https://doi.org/10.1088/1475-7516/2020/04/041

Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karincaoglu Y, et al. Clinical features and natural course of Behçet’s disease in 661 cases: a multicentre study. British Journal of Dermatology 2007;157(5):901-906. DOI: https://doi.org/10.1111/j.1365-2133.2007.08116.x

Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Behçet syndrome: a contemporary view. Nat Rev Rheumatol 14(2):107–119. https ://doi.org/10.1038/nrrhe um.2017.208 (published correction appears in Nat Rev Rheumatol. 2018 Jan 24;14 (2):119) DOI: https://doi.org/10.1038/nrrheum.2017.208

Seyahi E (2019) Phenotypes in Behçet’s syndrome. Intern Emerg Med 14(5):677–689. https ://doi.org/10.1007/s1173 9-019-02046 –y DOI: https://doi.org/10.1007/s11739-019-02046-y

Esatoglu SN, Hatemi G (2019) Update on the treatment of Behçet’s syndrome. Intern Emerg Med 14(5):661–675. https :// doi.org/10.1007/s1173 9-019-02035

Ben‐Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012; 42(2): 145‐ 153. DOI: https://doi.org/10.1007/s12016-010-8243-x

Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Ann Rheum Dis. 2018; 77(6): 808‐ 8187Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Ann Rheum Dis. 2018; 77(6): 808‐ 818

Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. Int J Antimicrob Agents. 2020; 56:105949. DOI: https://doi.org/10.1016/j.ijantimicag.2020.105949

Dursun, Recep, et al. "Management of Patients with Behçet's Disease During the COVID‐19 Pandemic." Dermatologic therapy (2020): e14063. DOI: https://doi.org/10.1111/dth.14063

Parra-Medina R, Sarmiento-Monroy JC, Rojas-Villarraga A, Garavito E, Montealegre-Gómez G, Gómez-López A. Colchicine as a possible therapeutic option in COVID-19 infection. Clinical Rheumatology 2020:1-2. DOI: https://doi.org/10.1007/s10067-020-05247-5

Lonesky, Timothy A., et al. "Hydroxychloroquine and colchicine induced myopathy." The Journal of rheumatology 36.11 (2009): 2617-2618. DOI: https://doi.org/10.3899/jrheum.081315

Downloads

Published

2020-11-24

How to Cite

Ezzouine, H., simou, M., louadghiri, A. E., Louardi, M., Khaoury, I., Mansour, A., Abidi, M. A., & Charra, B. (2020). COVID-19 ON BEHÇET’S DISEASE PATIENT : SHED LIGHT ON SHADOWS (CASE REPORT). International Journal of Research -GRANTHAALAYAH, 8(11), 49–52. https://doi.org/10.29121/granthaalayah.v8.i11.2020.1539